Melissa Reed1, Caitlyn Patrick1, Brianna Croft1, Natalie Walde1, Ioannis A Voutsadakis2,3. 1. Clinical Trials Unit, Sault Area Hospital, Sault Ste. Marie, Ontario, Canada. 2. Algoma District Cancer Program, Sault Area Hospital, Sault Ste. Marie, Ontario, P6B 0A8, Canada. ivoutsadakis@yahoo.com. 3. Section of Internal Medicine, Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, Ontario, Canada. ivoutsadakis@yahoo.com.
Abstract
BACKGROUND: Components of the metabolic syndrome (MetS) are involved in colorectal cancer development and the incidence of the disease is higher in obese and diabetic patients. Nevertheless, the value of these diseases or the MetS as a whole as prognostic markers once colorectal cancer is diagnosed is controversial. METHODS: Patients with metastatic colorectal cancer treated in our center over a 6-year period were reviewed and data on baseline characteristics of the patients and their cancers were extracted. Data on the presence and pharmacologic treatments of the four components of the MetS (obesity, diabetes, hypertension, and dyslipidemia) were also recorded. Overall survival (OS) and progression-free survival (PFS), Kaplan-Meier curves of the various groups were constructed and compared with the log-rank test. RESULTS: One hundred and twenty-three patients were included in the analysis. The prevalence of the four MetS components was 66.1% for overweight/obesity, 25.2% for diabetes, 61% for hypertension, and 41.5% for dyslipidemia. Among the four components of the metabolic syndrome, none was associated with either PFS or OS. Diabetes tended to approach significance for PFS (p = 0.08). The MetS as a whole did not influence survival outcome. MetS was not prognostic even if the overweight category was not considered as a positive element of the syndrome. CONCLUSION: These data suggest that diabetes or other metabolic syndrome elements are not prognostic factors for PFS or OS in metastatic colorectal cancer. Further investigation may be warranted with a focus on refinement of the metabolic evaluation.
BACKGROUND: Components of the metabolic syndrome (MetS) are involved in colorectal cancer development and the incidence of the disease is higher in obese and diabeticpatients. Nevertheless, the value of these diseases or the MetS as a whole as prognostic markers once colorectal cancer is diagnosed is controversial. METHODS:Patients with metastatic colorectal cancer treated in our center over a 6-year period were reviewed and data on baseline characteristics of the patients and their cancers were extracted. Data on the presence and pharmacologic treatments of the four components of the MetS (obesity, diabetes, hypertension, and dyslipidemia) were also recorded. Overall survival (OS) and progression-free survival (PFS), Kaplan-Meier curves of the various groups were constructed and compared with the log-rank test. RESULTS: One hundred and twenty-three patients were included in the analysis. The prevalence of the four MetS components was 66.1% for overweight/obesity, 25.2% for diabetes, 61% for hypertension, and 41.5% for dyslipidemia. Among the four components of the metabolic syndrome, none was associated with either PFS or OS. Diabetes tended to approach significance for PFS (p = 0.08). The MetS as a whole did not influence survival outcome. MetS was not prognostic even if the overweight category was not considered as a positive element of the syndrome. CONCLUSION: These data suggest that diabetes or other metabolic syndrome elements are not prognostic factors for PFS or OS in metastatic colorectal cancer. Further investigation may be warranted with a focus on refinement of the metabolic evaluation.
Authors: Hiroki Yuhara; Craig Steinmaus; Stephanie E Cohen; Douglas A Corley; Yoshihiro Tei; Patricia A Buffler Journal: Am J Gastroenterol Date: 2011-09-13 Impact factor: 10.864
Authors: Manasi S Shah; David R Fogelman; Kanwal Pratap Singh Raghav; John V Heymach; Hai T Tran; Zhi-Qin Jiang; Scott Kopetz; Carrie R Daniel Journal: Cancer Date: 2015-05-14 Impact factor: 6.860
Authors: Frank A Sinicrope; Nathan R Foster; Daniel J Sargent; Michael J O'Connell; Cathryn Rankin Journal: Clin Cancer Res Date: 2010-03-09 Impact factor: 12.531
Authors: Erin M Siegel; Cornelia M Ulrich; Elizabeth M Poole; Rebecca S Holmes; Paul B Jacobsen; David Shibata Journal: Cancer Control Date: 2010-01 Impact factor: 3.302
Authors: Katherine T Mills; Charles F Bellows; Aaron E Hoffman; Tanika N Kelly; Giuseppe Gagliardi Journal: Dis Colon Rectum Date: 2013-11 Impact factor: 4.585
Authors: C Giessen; U Graeven; R P Laubender; D P Modest; C Schulz; R Porschen; W Schmiegel; A Reinacher-Schick; S Hegewisch-Becker; S Stintzing; V Heinemann Journal: Ann Oncol Date: 2013-10-14 Impact factor: 32.976